Cargando…

Proadrenomedullin and copeptin in pediatric pneumonia: a prospective diagnostic accuracy study

BACKGROUND: Community-acquired-pneumonia is the leading cause of child mortality worldwide. Very few studies have explored the predictive value of Proadrenomedullin and Copeptin in pediatric severe pneumonia and bacteremia. METHODS: Proadrenomedullin and Copeptin were assessed as predictors for comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Alcoba, Gabriel, Manzano, Sergio, Lacroix, Laurence, Galetto-Lacour, Annick, Gervaix, Alain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4543464/
https://www.ncbi.nlm.nih.gov/pubmed/26286191
http://dx.doi.org/10.1186/s12879-015-1095-5
Descripción
Sumario:BACKGROUND: Community-acquired-pneumonia is the leading cause of child mortality worldwide. Very few studies have explored the predictive value of Proadrenomedullin and Copeptin in pediatric severe pneumonia and bacteremia. METHODS: Proadrenomedullin and Copeptin were assessed as predictors for complicated community-acquired pneumonia (bacteremia, empyema) in 88 children aged 0 to 16 years presenting to the pediatric emergency department, using B.R.A.H.M.S. Kryptor Compact pro-ADM and Copeptin with the TRACE technology (time-resolved amplified cryptase emission). STARD standard reporting was used. RESULTS: A complicated community-acquired pneumonia was found in 11 out of 88 children (12.5 %). Proadrenomedullin median values increased more than twofold, in complicated vs. uncomplicated (0.18 vs. 0.08 nmol/L, p = 0.039), and fivefold in bacteremic vs. non-bacteremic pneumonia (0.40 vs. 0.08 nmol/L, p = 0.02). Proadrenomedullin > 0.16 nmol/L showed 100 % sensitivity (95 % CI 39.8 – 100.0) and 70 % (95 % CI 58.7 – 79.7) specificity for bacteremia. Copeptin showed no added-value. CONCLUSIONS: Proadrenomedullin seems a reliable and available predictor for complicated CAP, and could therefore help the physician with the decision to hospitalize, and choose the antibiotics administration route. Larger studies are needed. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-015-1095-5) contains supplementary material, which is available to authorized users.